Table 3.
Comparison of Courses of Isavuconazole, Posaconazole, and Voriconazole Primary Prophylaxis in Patients Undergoing Treatment for Acute Myeloid Leukemia
| Characteristic | ISA | POS | P Valuea | VOR | P Valueb |
|---|---|---|---|---|---|
| Total patients, No. | 85 | 68 | 88 | ||
| Total courses, No. | 88 | 73 | 90 | ||
| Indication | |||||
| De novo AML, induction chemotherapy | |||||
| Patients, No. (% of total patients) | 38 (45) | 37 (54) | .25 | 72 (82) | < .0001 |
| Courses, No. (% of total courses) | 38 (43) | 37 (51) | .4 | 72 (80) | < .0001 |
| Duration of neutropenia, days, median (IQR) | 24.5 (21–44) | 31 (23–76) | .07 | 26 (19–42) | .9 |
| Duration of prophylaxis, days, median (IQR) | 20 (16–24) | 28 (16–62) | .09 | 19 (15–25) | .6 |
| Anthracycline chemotherapy, No. (% of courses per indication) | 29 (76.3) | 27 (73) | .8 | 61 (84.7) | .3 |
| R/R AML, reinduction/salvage chemotherapy | |||||
| Patients, No. (% of total patients) | 47 (55) | 31 (46) | 16 (18) | ||
| Courses, No. (% of total courses) | 50 (57) | 36 (49) | 18 (20) | ||
| Duration of neutropenia, days, median (IQR) | 28.5 (15–64) | 35 (16–57) | .9 | 38 (27–56) | .5 |
| Duration of prophylaxis, days, median (IQR) | 19.5 (16–32) | 22 (15–50) | .8 | 27 (16–43) | .4 |
| Anthracycline chemotherapy, No. (% of courses per indication) | 38 (75.3) | 27 (75) | 1 | 15 (83) | .7 |
Abbreviations: AML, acute myeloid leukemia; IQR, interquartile range; ISA, isavuconazole; POS, posaconazole; R/R, relapsed/refractory; VOR, voriconazole.
aISA vs POS.
bISA vs VOR.